Introduction
NSCLC, gastrointestinal tumors, tumor, cancer, Lung cancer, lung adenocarcinoma, primary lung cancer, lung cancer, gastrointestinal malignant neoplasms
GASTROINTESTINAL TUMORS, TUMOR, CANCER, DISEASE, LUNG CANCER, LUNG ADENOCARCINOMA, LUNG CANCER, SMALL CELL LUNG CANCER, ADHESION, OF LUNG ADENOCARCINOMA, LUNG METASTASES, NSCLC, LUNG CANCERS
Lung cancer, particularly non–small cell lung cancer (NSCLC), carries one of the highest rates of cancer-related morbidity and mortality worldwide.Therefore, thoracic surgeons continually strive for R0 oncologic disease clearance at index operation.A promising target is the glycoprotein carcinoembryonic antigen–related cell adhesion molecule type 5 (CEACAM5), also known as carcinoembryonic antigen (CEA). Although the glycoprotein has been extensively studied and used for screening, diagnosis, and prognosis in gastrointestinal malignant neoplasms, it has been relatively underused in lung cancer, although 30% to 80% of lung adenocarcinomas express this surface receptor.In this study, we explored the safety, efficacy, and specificity of SGM-101 during IMI-guided lung nodule resections. First, we explored a large national cancer database for CEACAM5 RNA expression levels in various lung cancers. Second, we assessed glycoprotein expression levels in 33 patients diagnosed with lung adenocarcinoma from our institution to assess local rates of CEACAM5 tumor presence. Third, we performed an open-label nonrandomized controlled trial in patients with gastrointestinal tumors who presented with lung metastases based on serum CEA levels as a control and compared the results in subsequent patients who underwent SGM-101–guided primary lung cancer resection. We hypothesized that SGM-101 would specifically localize to CEACAM5-positive lung nodules and allow lesion localization in vivo, ex vivo, and on immunohistopathologic assessment.